Skip to main content
Erschienen in: Digestive Diseases and Sciences 4/2018

08.02.2018 | Original Article

Role of Esophageal Metal Stents Placement and Combination Therapy in Inoperable Esophageal Carcinoma: A Systematic Review and Meta-analysis

verfasst von: Andrew Lai, Seth Lipka, Ambuj Kumar, Sajiv Sethi, David Bromberg, Nanxing Li, Huafeng Shen, Lilia Stefaniwsky, Patrick Brady

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

More than 50% of patients with esophageal cancer already have inoperable disease at the time of diagnosis. Controversy surrounds the outcomes of patients with advanced esophageal cancer who receive palliative care by either stent alone or stent plus an additional modality. We set out to perform a systematic review and meta-analysis of studies assessing the use of metal stents as treatment options for symptomatic improvement, survival, and adverse events.

Methods

We searched Embase, MEDLINE, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception until January 14, 2016, as well as other databases for randomized controlled trials (RCTs) comparing esophageal stent versus either esophageal stent plus brachytherapy, radiotherapy, or chemotherapy. For quality assurance purposes throughout the systematic review, multiple independent extractions were performed, and the process was executed as per the standards of the Cochrane collaboration. Primary outcomes were mean change in dysphagia score, overall survival, and quality of life. Secondary outcomes were adverse events including fever, severe pain, aspiration, fistula, stent migration, perforation, and restenosis.

Results

Eight RCTs enrolling 732 patients were included with three distinct comparisons: stents combination therapy vs stents alone (5 studies, n = 417), stents alone versus brachytherapy alone (2 studies, n = 274), and stents + brachytherapy vs brachytherapy alone (1 study, n = 41). Stents combination therapy was defined as stents plus radiotherapy, chemotherapy, or both. Mean change in dysphagia scores favored stents combination therapy versus stents alone, and the effect was seen in patients surviving longer than 3 months. Stents combination therapy was also associated with a more favorable overall survival. The risks of stent migration, aspiration pneumonia, and restenosis were lower in the stents combination group compared to stents alone, while the risks of severe pain, hemorrhage, and fistula formation were higher. Changes in dysphagia scores and overall survival did not differ significantly in the brachytherapy-alone vs stents-alone comparison. The risk of fistula formation and hemorrhage were higher in the stents-alone group, while the risk of perforation was lower, compared to brachytherapy alone. Quality of life improvements were seen in all treatment groups, but were not pooled in analysis due to differing methods of measurement.

Discussion

While there appears to be no immediate short-term differences, those who live longer than 3 months experience a significant improvement in dysphagia score using a stents combination therapy approach vs stents alone. The combination therapy significantly improves the overall survival as well as showed improvements in quality of life scores. Larger randomized controlled trials are needed to assess improvements in dysphagia score, overall survival, quality of life, and adverse events.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.CrossRefPubMed
2.
Zurück zum Zitat Bergquist H, Johnsson A, Hammerlid E, et al. Factors predicting survival in patients with advanced oesophageal cancer: a prospective multicentre evaluation. Aliment Pharmacol Ther. 2008;27:385–395.CrossRefPubMed Bergquist H, Johnsson A, Hammerlid E, et al. Factors predicting survival in patients with advanced oesophageal cancer: a prospective multicentre evaluation. Aliment Pharmacol Ther. 2008;27:385–395.CrossRefPubMed
3.
Zurück zum Zitat Talback M, Rosen M, Stenbeck M, et al. Cancer patient survival in Sweden at the beginning of the third millennium–predictions using period analysis. Cancer Causes Control. 2004;15:967–976.CrossRefPubMed Talback M, Rosen M, Stenbeck M, et al. Cancer patient survival in Sweden at the beginning of the third millennium–predictions using period analysis. Cancer Causes Control. 2004;15:967–976.CrossRefPubMed
5.
Zurück zum Zitat Brierley JD, Oza AM. Radiation and chemotherapy in the management of malignant esophageal strictures. Gastrointest Endosc Clin N Am. 1998;8:451–463.PubMed Brierley JD, Oza AM. Radiation and chemotherapy in the management of malignant esophageal strictures. Gastrointest Endosc Clin N Am. 1998;8:451–463.PubMed
6.
Zurück zum Zitat Amdal CD, Jacobsen AB, Sandstad B, et al. Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial. Radiother Oncol. 2013;107:428–433.CrossRefPubMed Amdal CD, Jacobsen AB, Sandstad B, et al. Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial. Radiother Oncol. 2013;107:428–433.CrossRefPubMed
7.
Zurück zum Zitat Wenger U, Johnsson E, Bergquist H, et al. Health economic evaluation of stent or endoluminal brachytherapy as a palliative strategy in patients with incurable cancer of the oesophagus or gastro-oesophageal junction: results of a randomized clinical trial. Eur J Gastroenterol Hepatol. 2005;17:1369–1377.CrossRefPubMed Wenger U, Johnsson E, Bergquist H, et al. Health economic evaluation of stent or endoluminal brachytherapy as a palliative strategy in patients with incurable cancer of the oesophagus or gastro-oesophageal junction: results of a randomized clinical trial. Eur J Gastroenterol Hepatol. 2005;17:1369–1377.CrossRefPubMed
8.
Zurück zum Zitat Dai Y, Li C, Xie Y, et al. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev. 2014;10:CD005048. Dai Y, Li C, Xie Y, et al. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev. 2014;10:CD005048.
9.
Zurück zum Zitat Bergquist H, Wenger U, Johnsson E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus. 2005;18:131–139.CrossRefPubMed Bergquist H, Wenger U, Johnsson E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus. 2005;18:131–139.CrossRefPubMed
10.
Zurück zum Zitat Steyerberg EW, Homs MY, Stokvis A, et al. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc. 2005;62:333–340.CrossRefPubMed Steyerberg EW, Homs MY, Stokvis A, et al. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc. 2005;62:333–340.CrossRefPubMed
11.
Zurück zum Zitat de Vet HCW, Eisinga A, Riphagen II, Aertgeerts B, Pewsner D. Chapter 7: searching for studies. In: Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 0.4 [updated September 2008]. The Cochrane Collaboration; 2008. de Vet HCW, Eisinga A, Riphagen II, Aertgeerts B, Pewsner D. Chapter 7: searching for studies. In: Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 0.4 [updated September 2008]. The Cochrane Collaboration; 2008.
12.
13.
Zurück zum Zitat Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration: www.cochrane-handbook.org; 2011. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration: www.​cochrane-handbook.​org; 2011.
14.
Zurück zum Zitat Guyatt GH, Oxman AD, Schunemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380–382.CrossRefPubMed Guyatt GH, Oxman AD, Schunemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380–382.CrossRefPubMed
15.
Zurück zum Zitat Moher D, Altman DG, Liberati A, et al. PRISMA statement. Epidemiology. 2011;22:128. (author reply 128).CrossRefPubMed Moher D, Altman DG, Liberati A, et al. PRISMA statement. Epidemiology. 2011;22:128. (author reply 128).CrossRefPubMed
16.
Zurück zum Zitat Deeks J, Higgins J, Altman D, et al. Chapter 9: analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Deeks J, Higgins J, Altman D, et al. Chapter 9: analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
18.
Zurück zum Zitat Sterne JE, Moher D. Chapter 10: addressing reporting biases. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Sterne JE, Moher D. Chapter 10: addressing reporting biases. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
19.
Zurück zum Zitat Homs MY, Essink-Bot ML, Borsboom GJ, et al. Quality of life after palliative treatment for oesophageal carcinoma—a prospective comparison between stent placement and single dose brachytherapy. Eur J Cancer. 2004;40:1862–1871.CrossRefPubMed Homs MY, Essink-Bot ML, Borsboom GJ, et al. Quality of life after palliative treatment for oesophageal carcinoma—a prospective comparison between stent placement and single dose brachytherapy. Eur J Cancer. 2004;40:1862–1871.CrossRefPubMed
20.
Zurück zum Zitat Homs MY, Steyerberg EW, Eijkenboom WM, et al. Palliative treatment of esophageal cancer with dysphagia: more favourable outcome from single-dose internal brachytherapy than from the placement of a self-expanding stent; a multicenter randomised study. Ned Tijdschr Geneeskd. 2005;149:2800–2806.PubMed Homs MY, Steyerberg EW, Eijkenboom WM, et al. Palliative treatment of esophageal cancer with dysphagia: more favourable outcome from single-dose internal brachytherapy than from the placement of a self-expanding stent; a multicenter randomised study. Ned Tijdschr Geneeskd. 2005;149:2800–2806.PubMed
21.
Zurück zum Zitat Homs MY, Steyerberg EW, Eijkenboom WM, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet. 2004;364:1497–1504.CrossRefPubMed Homs MY, Steyerberg EW, Eijkenboom WM, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet. 2004;364:1497–1504.CrossRefPubMed
22.
Zurück zum Zitat Zhu HD, Guo JH, Mao AW, et al. Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial. Lancet Oncol. 2014;15:612–619.CrossRefPubMed Zhu HD, Guo JH, Mao AW, et al. Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial. Lancet Oncol. 2014;15:612–619.CrossRefPubMed
23.
Zurück zum Zitat Zhu HD, Guo JH, Teng GJ. Irradiation vs. conventional self-expandable metal stents for the treatment of unresectable esophageal cancer: a multicenter randomized controlled trial. Cardiovasc Intervent Radiol. 2014;37:S223. Zhu HD, Guo JH, Teng GJ. Irradiation vs. conventional self-expandable metal stents for the treatment of unresectable esophageal cancer: a multicenter randomized controlled trial. Cardiovasc Intervent Radiol. 2014;37:S223.
24.
Zurück zum Zitat Fu JH, Rong TH, Li XD, et al. Treatment of unresectable esophageal carcinoma by stenting with or without radiochemotherapy. Zhonghua Zhong Liu Za Zhi. 2004;26:109–111.PubMed Fu JH, Rong TH, Li XD, et al. Treatment of unresectable esophageal carcinoma by stenting with or without radiochemotherapy. Zhonghua Zhong Liu Za Zhi. 2004;26:109–111.PubMed
25.
Zurück zum Zitat Guo JH, Teng GJ, Zhu GY, et al. Self-expandable esophageal stent loaded with 125I seeds: initial experience in patients with advanced esophageal cancer. Radiology. 2008;247:574–581.CrossRefPubMed Guo JH, Teng GJ, Zhu GY, et al. Self-expandable esophageal stent loaded with 125I seeds: initial experience in patients with advanced esophageal cancer. Radiology. 2008;247:574–581.CrossRefPubMed
26.
Zurück zum Zitat Lu B, Wu M, Wu P, et al. Clinical effect and safety of 125I particle stent on treatment of postoperative esophageal stricture for patients with advanced esophageal cancer. Chin J Radiol (China). 2014;48:311–315. Lu B, Wu M, Wu P, et al. Clinical effect and safety of 125I particle stent on treatment of postoperative esophageal stricture for patients with advanced esophageal cancer. Chin J Radiol (China). 2014;48:311–315.
27.
Zurück zum Zitat Javed A, Pal S, Dash NR, et al. Palliative stenting with or without radiotherapy for inoperable esophageal carcinoma: a randomized trial. J Gastrointest Cancer. 2012;43:63–69.CrossRefPubMed Javed A, Pal S, Dash NR, et al. Palliative stenting with or without radiotherapy for inoperable esophageal carcinoma: a randomized trial. J Gastrointest Cancer. 2012;43:63–69.CrossRefPubMed
28.
Zurück zum Zitat Spaander MC, Baron TH, Siersema PD, et al. Esophageal stenting for benign and malignant disease: European society of gastrointestinal endoscopy (ESGE) clinical guideline. Endoscopy. 2016;48:939–948.CrossRefPubMed Spaander MC, Baron TH, Siersema PD, et al. Esophageal stenting for benign and malignant disease: European society of gastrointestinal endoscopy (ESGE) clinical guideline. Endoscopy. 2016;48:939–948.CrossRefPubMed
29.
Zurück zum Zitat Kanikowski M, Skowronek J, Kubaszewska M, et al. HDR brachytherapy (HDR-BT) combined with stent placement in palliative treatment of esophageal cancer. J Contemp Brachyther. 2009;1:25–32. Kanikowski M, Skowronek J, Kubaszewska M, et al. HDR brachytherapy (HDR-BT) combined with stent placement in palliative treatment of esophageal cancer. J Contemp Brachyther. 2009;1:25–32.
Metadaten
Titel
Role of Esophageal Metal Stents Placement and Combination Therapy in Inoperable Esophageal Carcinoma: A Systematic Review and Meta-analysis
verfasst von
Andrew Lai
Seth Lipka
Ambuj Kumar
Sajiv Sethi
David Bromberg
Nanxing Li
Huafeng Shen
Lilia Stefaniwsky
Patrick Brady
Publikationsdatum
08.02.2018
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 4/2018
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-4957-z

Weitere Artikel der Ausgabe 4/2018

Digestive Diseases and Sciences 4/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.